Your browser doesn't support javascript.
loading
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.
Mai, Elias K; Hielscher, Thomas; Bertsch, Uta; Schlenzka, Jana; Salwender, Hans J; Munder, Markus; Gerecke, Christian; Dührsen, Ulrich; Brossart, Peter; Neben, Kai; Hillengass, Jens; Raab, Marc S; Merz, Maximilian; Baertsch, Marc-Andrea; Jauch, Anna; Hose, Dirk; Martin, Hans; Lindemann, Hans-Walter; Blau, Igor W; Scheid, Christof; Weisel, Katja C; Goldschmidt, Hartmut.
Affiliation
  • Mai EK; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany. elias.mai@med.uni-heidelberg.de.
  • Hielscher T; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bertsch U; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Schlenzka J; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Salwender HJ; Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
  • Munder M; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
  • Gerecke C; Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
  • Dührsen U; Department of Hematology, University Clinic Essen, Essen, Germany.
  • Brossart P; University Hospital Bonn, Bonn, Germany.
  • Neben K; Department of Hematology and Oncology, Klinikum Baden Baden, Baden Baden, Germany.
  • Hillengass J; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Raab MS; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Merz M; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Baertsch MA; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Hose D; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
  • Martin H; Department of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, Frankfurt, Germany.
  • Lindemann HW; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
  • Blau IW; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
  • Scheid C; Department of Internal Medicine I, University Hospital Köln, Köln, Germany.
  • Weisel KC; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
  • Goldschmidt H; Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Leukemia ; 33(1): 258-261, 2019 01.
Article in En | MEDLINE | ID: mdl-29959413
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2019 Document type: Article Affiliation country: Alemania
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2019 Document type: Article Affiliation country: Alemania